Vorinostat in Treating Patients With Metastatic Melanoma of the Eye

ClinicalTrials.gov ID: NCT01587352

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01587352. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body (metastatic). Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study identification

NCT ID: NCT01587352
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Cancer Institute (NCI); NIH
Enrollment: 40 participants

Conditions and interventions

Conditions

Interventions

Laboratory Biomarker Analysis Other
Vorinostat Drug

Other · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 29, 2012 (Actual)
Primary completion: Dec 31, 2026 (Estimated)
Completion: Dec 31, 2026 (Estimated)
Last update posted: Nov 12, 2026

2012 – 2026

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Vanderbilt University/Ingram Cancer Center	Nashville	Tennessee	37232	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01587352, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 12, 2026 · Synced Nov 14, 2026